Novel targeted therapies in lymphoid neoplasia: from apoptosis activation to microenvironment harnessing

In the last years  it has been acknowledge that the origin of most of lymphoid neoplasia derives from a tight collaboration between specific genetic alterations and the support of the accompanying non-tumor cells, the so- called tumor microenvironment. A potentially effective treatment must attack tumor cells with targeted therapies and, at the same time, dismantle the 'contact network' that protects it, that is, the microenvironment. In this seminar we will